Your browser is no longer supported. Please, upgrade your browser.
ALLO Allogene Therapeutics, Inc. daily Stock Chart
Allogene Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.99 Insider Own3.20% Shs Outstand108.96M Perf Week3.49%
Market Cap5.85B Forward P/E- EPS next Y-2.60 Insider Trans-24.74% Shs Float65.92M Perf Month3.40%
Income-207.50M PEG- EPS next Q-0.54 Inst Own53.90% Short Float17.43% Perf Quarter135.36%
Sales- P/S- EPS this Y-4.90% Inst Trans3.45% Short Ratio9.03 Perf Half Y71.33%
Book/sh5.57 P/B7.98 EPS next Y-15.00% ROA-29.30% Target Price53.00 Perf Year66.02%
Cash/sh3.75 P/C11.86 EPS next 5Y- ROE-33.10% 52W Range17.43 - 55.00 Perf YTD71.13%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-18.06% Beta-
Dividend %- Quick Ratio18.80 Sales past 5Y- Gross Margin- 52W Low158.55% ATR2.80
Employees215 Current Ratio18.80 Sales Q/Q- Oper. Margin- RSI (14)60.55 Volatility6.08% 5.74%
OptionableYes Debt/Eq0.00 EPS Q/Q-54.00% Profit Margin- Rel Volume0.39 Prev Close44.46
ShortableYes LT Debt/Eq0.00 EarningsMay 06 BMO Payout- Avg Volume1.27M Price45.06
Recom1.90 SMA205.77% SMA5010.89% SMA20053.13% Volume214,832 Change1.36%
Jun-01-20Downgrade Raymond James Outperform → Mkt Perform
May-29-20Reiterated H.C. Wainwright Buy $42 → $55
May-19-20Upgrade ROTH Capital Neutral → Buy $26 → $60
May-15-20Upgrade Guggenheim Neutral → Buy
May-14-20Reiterated H.C. Wainwright Buy $35 → $42
May-14-20Downgrade SunTrust Buy → Hold $29 → $32
Apr-13-20Initiated SunTrust Buy $29
Mar-13-20Initiated H.C. Wainwright Buy $35
Mar-05-20Initiated Stifel Hold $27
Feb-24-20Initiated Berenberg Hold $27
Dec-18-19Initiated JMP Securities Mkt Outperform $37
Nov-04-19Initiated Canaccord Genuity Buy $36
Aug-09-19Initiated BTIG Research Buy $37
Jun-05-19Initiated ROTH Capital Neutral $26
May-31-19Initiated Guggenheim Neutral
May-23-19Initiated Stifel Hold
Mar-29-19Initiated Piper Jaffray Overweight $50
Mar-15-19Initiated Raymond James Outperform
Mar-14-19Initiated William Blair Outperform
Nov-05-18Initiated JP Morgan Neutral $29
Jul-07-20 08:30AM  
Jul-05-20 03:31PM  
Jul-01-20 10:54AM  
Jun-26-20 03:30PM  
Jun-22-20 04:30PM  
Jun-14-20 11:38AM  
Jun-10-20 11:30AM  
Jun-05-20 11:32AM  
Jun-03-20 08:30AM  
Jun-02-20 07:14AM  
Jun-01-20 09:05PM  
May-29-20 10:32AM  
May-28-20 11:21AM  
May-27-20 10:02AM  
May-26-20 04:30PM  
May-22-20 11:30AM  
May-19-20 08:55AM  
May-18-20 09:22AM  
May-15-20 07:49AM  
May-14-20 01:06PM  
May-13-20 05:00PM  
May-11-20 08:30AM  
May-07-20 10:51AM  
May-06-20 07:30AM  
May-05-20 11:45AM  
Apr-29-20 11:54AM  
Apr-28-20 04:39PM  
Apr-27-20 08:30AM  
Apr-22-20 07:15AM  
Apr-17-20 11:30AM  
Apr-16-20 12:00PM  
Apr-01-20 08:30AM  
Mar-28-20 09:10PM  
Mar-24-20 07:00AM  
Mar-23-20 12:00PM  
Mar-20-20 08:54AM  
Mar-17-20 06:30AM  
Mar-16-20 12:09AM  
Mar-02-20 06:15AM  
Mar-01-20 07:15AM  
Feb-27-20 04:30AM  
Feb-19-20 08:30AM  
Feb-06-20 08:30AM  
Jan-13-20 06:00AM  
Jan-02-20 08:30AM  
Dec-20-19 05:16PM  
Nov-11-19 08:30AM  
Nov-06-19 09:02AM  
Nov-05-19 07:30AM  
Oct-29-19 08:30AM  
Oct-25-19 11:12AM  
Oct-18-19 11:22AM  
Oct-03-19 05:53PM  
Sep-19-19 08:00AM  
Sep-18-19 05:33PM  
Sep-03-19 08:30AM  
Aug-20-19 10:00AM  
Aug-07-19 11:24PM  
Aug-05-19 06:00AM  
Jul-29-19 08:30AM  
Jul-16-19 08:00AM  
Jun-22-19 07:30AM  
Jun-04-19 07:45AM  
Jun-03-19 11:00AM  
May-29-19 08:30AM  
May-07-19 10:24PM  
May-05-19 09:19AM  
May-01-19 08:30AM  
Apr-30-19 08:30AM  
Apr-15-19 08:00AM  
Apr-03-19 04:30PM  
Apr-01-19 01:00PM  
Mar-14-19 10:14AM  
Mar-08-19 08:00AM  
Feb-20-19 03:46PM  
Feb-08-19 10:40AM  
Feb-05-19 08:00AM  
Jan-29-19 09:38AM  
Jan-28-19 08:30AM  
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. It is also developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. Allogene Therapeutics, Inc. was founded in 2017 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
TPG Group Holdings (SBS) Advis10% OwnerJun 30Sale42.2159,7472,522,05219,716,306Jun 30 04:53 PM
TPG Group Holdings (SBS) Advis10% OwnerJun 29Sale43.2724,9041,077,54419,776,053Jun 30 04:53 PM
TPG Group Holdings (SBS) Advis10% OwnerJun 26Sale44.0150022,00519,800,957Jun 30 04:53 PM
TPG Group Holdings (SBS) Advis10% OwnerJun 25Sale44.1972,3593,197,32719,801,457Jun 25 06:24 PM
TPG Group Holdings (SBS) Advis10% OwnerJun 24Sale43.9315,269670,71419,873,816Jun 25 06:24 PM
TPG Group Holdings (SBS) Advis10% OwnerJun 23Sale43.98132,2255,814,61019,889,085Jun 25 06:24 PM
TPG Group Holdings (SBS) Advis10% OwnerJun 22Sale42.83172,4257,384,72120,021,310Jun 22 06:25 PM
TPG Group Holdings (SBS) Advis10% OwnerJun 19Sale42.0447,7672,008,30620,193,735Jun 22 06:25 PM
TPG Group Holdings (SBS) Advis10% OwnerJun 18Sale42.1494,6003,986,59520,241,502Jun 22 06:25 PM
TPG Group Holdings (SBS) Advis10% OwnerJun 17Sale42.1887,3193,683,48220,336,102Jun 17 06:13 PM
TPG Group Holdings (SBS) Advis10% OwnerJun 16Sale42.20174,5117,364,67820,423,421Jun 17 06:13 PM
TPG Group Holdings (SBS) Advis10% OwnerJun 15Sale42.14129,1545,442,88520,597,932Jun 17 06:13 PM
Belldegrun ArieDirectorJun 04Buy47.00146,3826,879,9541,798,163Jun 04 04:04 PM
TPG Group Holdings (SBS) Advis10% OwnerJun 04Sale47.111,81885,63820,727,086Jun 05 05:43 PM
TPG Group Holdings (SBS) Advis10% OwnerJun 03Sale47.40487,40223,102,51420,728,904Jun 05 05:43 PM
SCHMIDT ERIC THOMASChief Financial OfficerMar 16Sale19.735,450107,50847,257Mar 18 04:32 PM
MOORE ALISONChief Technical OfficerMar 16Sale19.193,75071,98063,021Mar 18 04:32 PM
Chang David DPresident and CEOMar 16Sale19.3120,335392,6152,214,914Mar 18 04:31 PM